Want to see CGEM full AI Analyst Report?

Cullinan Management (CGEM) Price & Analysis

359 Followers

CGEM Stock Chart & Stats

$17.10

-$0.18(-1.04%)

At close: Jul 24 4:00 PM EDT

$17.10

-$0.18(-1.04%)

Day’s Range― - ―

52-Week Range$5.68 - $19.43

Previous CloseN/A

Volume316.66K

Average Volume (3M)990.97K

Market Cap

$1.01B

Enterprise Value$517.55

Total Cash (Recent Filing)$334.54M

Total Debt (Recent Filing)$2.07M

Price to Earnings (P/E)―

Beta0.96

Next Earnings

Nov 05, 2026

EPS Estimate

-0.85

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.56

Shares Outstanding61,458,046

10 Day Avg. Volume530,726

30 Day Avg. Volume990,974

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)1.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.48

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$33.67

Price Target Upside96.88% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-3.04

Revenue Forecast (FY)$17.85M

Bulls Say, Bears Say

Bulls Say

Promising Autoimmune Pipeline DataRobust early Phase 1 efficacy and favorable safety for CLN-978 and velinotamig support a differentiated T‑cell engager franchise in autoimmune disease. Durable because positive disease‑modifying signals and outpatient subcutaneous dosing can translate into sustained clinical development value and future commercial opportunity if later trials confirm benefits.

Regulatory De‑risking For Oncology AssetEnd‑of‑Phase 1 agreement with the FDA to start a potentially registrational Phase 2 provides structural de‑risking for CLN‑049. An agreed trial design and pathway to registrational data shorten development uncertainty, increase clarity for commercialization prospects, and improve partner or investor interest over the medium term.

Very Low Financial LeverageMinimal debt materially reduces fixed financial obligations and bankruptcy risk for a cash‑burning biotech. This structural conservatism preserves strategic flexibility to raise equity or pursue partnerships for R&D financing, sustaining operational continuity during multi‑year development programs.

Bears Say

Large, Persistent Cash BurnSustained multi‑year negative operating and free cash flow consumes capital and creates runway pressure. Intensifying burn relative to prior periods heightens the probability of dilutive financings or program slowdowns, constraining long‑term execution unless spending is reduced or new funding secured.

Pre‑commercial Business With No Meaningful RevenueLack of recurring sales means enterprise value hinges entirely on clinical and regulatory success. This binary, long‑dated commercialization risk increases volatility of cash flows and makes long‑term sustainability dependent on successful trial outcomes and flawless launch execution, not existing operations.

Erosion Of Shareholders' EquityMaterial decline in equity indicates the company is consuming shareholder capital to fund operations, producing negative returns on invested capital. Over time this raises the likelihood of dilutive financing, reduces strategic optionality, and signals persistent value destruction unless clinical programs convert to commercial revenues.

Cullinan Management News

Cullinan Therapeutics reports Q2 EPS (81c), consensus (85c)

“At our recent Immunology Day event, we shared compelling initial clinical data for CLN-978 and velinotamig, two T...

22h ago

CGEM

Cullinan Therapeutics price target raised to $39 from $38 at BTIG

BTIG raised the firm’s price target on Cullinan Therapeutics (CGEM) to $39 from $38 and keeps a Buy...

9d ago

CGEM

Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA

Cullinan Therapeutics (CGEM) announced feedback from the FDA following an End-of-Phase 1 meeting for CLN-049, a FLT3xCD3 T...

10d ago

CGEM

Cullinan Therapeutics management to meet with BTIG

Biotechnology Analyst Harrison holds a group dinner meeting with management in New York on July 21 at 5:30...

24d ago

CGEM

Cullinan Maintained at Buy as Advancing Autoimmune and Oncology Pipeline Supports Unchanged $36 Price Target

Cullinan Management, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Boris Peaker from...

12h ago

CGEM

Cullinan Therapeutics Launches Early Trial of Velinotamig in Hard‑to‑Treat Blood Disorders

Cullinan Therapeutics Inc ($CGEM) announced an update on their ongoing clinical study. The study, titled “A Phase 1b/2a...

7d ago

CGEM

Analyst Reiterates Buy on CGEM as CLN-049 Advances Toward Registrational Phase 2; Price Target Raised to $39 on Improved Risk-Reward

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Cullinan Management, with a...

9d ago

CGEM

Cullinan Therapeutics Shareholders Back Directors and Governance Measures

Cullinan Management ( ($CGEM) ) just unveiled an announcement. Cullinan Therapeutics held its Annual Meeting of Stockholders on...

2M ago

CGEM

Cullinan Therapeutics price target raised to $46 from $33 at Clear Street

Clear Street raised the firm’s price target on Cullinan Therapeutics (CGEM) to $46 from $33 and keeps a...

2M ago

CGEM

Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data

Cullinan Management ( ($CGEM) ) has shared an announcement. On June 10, 2026, Cullinan Therapeutics reported updated Phase...

2M ago

CGEM

Cullinan Therapeutics reports CLN-978, velinotamig data

Cullinan Therapeutics (CGEM) reported clinical data and outlined global clinical development plans for CLN-978, a CD19xCD3 T cell...

2M ago

CGEM

Buy Rating on Cullinan Reinforced by Encouraging Early CLN-978 Autoimmune Data and High Upside Potential

In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on Cullinan Management, with a...

2M ago

CGEM

Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data

An update from Cullinan Management ( ($CGEM) ) is now available. On June 6, 2026, Cullinan Therapeutics presented...

2M ago

CGEM

Cullinan Therapeutics Reiterated as Buy on Promising CLN-978 Data; $30 Price Target Maintained

Morgan Stanley analyst Sean Laaman maintained a Buy rating on Cullinan Management yesterday and set a price target...

2M ago

CGEM

CGEM FAQ

What was Cullinan Therapeutics Inc’s price range in the past 12 months?

Cullinan Therapeutics Inc lowest stock price was $5.68 and its highest was $19.43 in the past 12 months.

What is Cullinan Therapeutics Inc’s market cap?

Cullinan Therapeutics Inc’s market cap is $1.01B.

When is Cullinan Therapeutics Inc’s upcoming earnings report date?

Cullinan Therapeutics Inc’s upcoming earnings report date is Nov 05, 2026 which is in 90 days.

How were Cullinan Therapeutics Inc’s earnings last quarter?

Cullinan Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.799 by -$0.011.

Is Cullinan Therapeutics Inc overvalued?

According to Wall Street analysts Cullinan Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cullinan Therapeutics Inc pay dividends?

Cullinan Therapeutics Inc does not currently pay dividends.

What is Cullinan Therapeutics Inc’s EPS estimate?

Cullinan Therapeutics Inc’s EPS estimate is -0.85.

How many shares outstanding does Cullinan Therapeutics Inc have?

Cullinan Therapeutics Inc has 61,458,046 shares outstanding.

What happened to Cullinan Therapeutics Inc’s price movement after its last earnings report?

Cullinan Therapeutics Inc reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.799. Following the earnings report the stock price went up 1.931%.

Which hedge fund is a major shareholder of Cullinan Therapeutics Inc?

Currently, no hedge funds are holding shares in CGEM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cullinan Management Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-30.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cullinan Therapeutics Inc

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.

Cullinan Management (CGEM) Earnings & Revenues

Historic Earnings Reports

CGEM Stock 12 Month Forecast

Average Price Target

$33.67

▲(96.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","26":"$26","47":"$47","15.5":"$15.5","36.5":"$36.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,15.5,26,36.5,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.5,18.76923076923077,21.03846153846154,23.307692307692307,25.576923076923077,27.846153846153847,30.115384615384613,32.38461538461539,34.65384615384615,36.92307692307692,39.19230769230769,41.46153846153846,43.730769230769226,{"y":46,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.5,17.82051282051282,19.141025641025642,20.46153846153846,21.78205128205128,23.102564102564102,24.42307692307692,25.74358974358974,27.064102564102562,28.384615384615383,29.705128205128204,31.025641025641022,32.34615384615384,{"y":33.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.5,17.076923076923077,17.653846153846153,18.23076923076923,18.807692307692307,19.384615384615383,19.96153846153846,20.53846153846154,21.115384615384613,21.692307692307693,22.269230769230766,22.846153846153847,23.423076923076923,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.99,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.43,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.21,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >